Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bioray Biotech Co., Ltd specializes in the development and manufacturing of biopharmaceuticals, particularly in the areas of oncology and autoimmune diseases. The company operates primarily in Taiwan and has established a competitive edge through its proprietary drug formulation technologies and a robust pipeline of clinical trials.
Bioray generates revenue primarily through the sale of its proprietary biopharmaceutical products, which are often sold at premium prices due to their unique formulations. The company also engages in contract manufacturing for other biotech firms, leveraging its advanced production capabilities. Its competitive advantages include a strong R&D focus, a well-established regulatory compliance track record, and strategic partnerships with research institutions.
Progress in clinical trials for new oncology drugs
Regulatory approvals for new drug formulations
Partnership announcements with larger pharmaceutical companies
Market expansion into Southeast Asia
Regulatory changes impacting drug approval processes
Technological disruption in biopharmaceutical manufacturing
Emergence of generic competitors for proprietary drugs
Increased competition from larger pharmaceutical companies with more resources
Low liquidity risk due to a high current ratio
Potential risks associated with reliance on a limited number of key products
moderate - The demand for biopharmaceuticals can be influenced by overall healthcare spending, which is correlated with GDP growth.
Interest rates affect Bioray's cost of capital for R&D investments. Higher rates could increase financing costs, potentially impacting growth initiatives.
minimal - The company maintains a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors are likely attracted to the company's strong revenue growth potential and innovative drug pipeline.
high - The stock may exhibit high volatility due to the binary nature of clinical trial outcomes and regulatory approvals.
